Karolinska

Karolinska Development AB is a venture capital firm based in Stockholm, Sweden, established in 2003. The firm specializes in early-stage investments in the life sciences and healthcare sectors, focusing on pharmaceutical research and development, biotechnology, medical technology, and related fields. Karolinska Development aims to create value by selecting commercially attractive medical innovations, developing them to enhance their return on investment, and subsequently commercializing these innovations through sales or out-licensing agreements. The firm primarily targets projects within the Nordic region, particularly in Sweden, and typically invests in up to five projects annually, often collaborating with innovators who serve as board members and advisors. With a structured selection process and a focus on minimizing operational costs in the initial stages, Karolinska Development seeks to advance its portfolio companies until they reach critical milestones for valuation increases. The firm prefers to exit investments at the Phase II stage of product development, which offers significant potential for successful negotiation of licensing or sales agreements.